Ischaemic stroke

18 trials 6 recruiting MedDRA PT
18 Registered trials
6 Recruiting
16 Unique sponsors
21 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
D Dermatology (ATC D) 1
V Various (ATC V) 3
B Haematology (ATC B) 6
R Respiratory (ATC R) 1
L Oncology (ATC L) 3
N Neurology/Psychiatry (ATC N) 2
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 16 substances
Monoclonal antibody 1 substance
Supportive / diluent 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Kinase inhibitor 1 substance
Antiplatelet / NSAID 1 substance
Phase III: 5 Phase II/III: 2 Phase II: 8 Phase IV: 2 Phase I: 1

Filter these 18 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 18 trials

Phase III

5 trials
  • Assistance Publique Hopitaux De Paris Academic
    TENECTEPLASE
    2024-520414-21-00 1 country n=486
    Pending
  • Foundation For The Study Of Nanoneuroscience And Neuroregeneration Academic
    CEREBROLYSIN CONCENTRATE; SODIUM CHLORIDE
    2025-521350-41-01 1 country 2025 n=416
    Recruiting
  • Karolinska Institutet Academic
    IMATINIB MESILATE
    2023-506178-11-00 1 country 2025 n=680
    Halted
  • Oslo University Hospital HF Academic
    IMP not specified
    2023-509907-34-01 3 countries 2025 n=500
    Recruiting
  • Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu Academic
    ALLOPURINOL
    2024-517610-15-00 1 country 2024 n=1,116
    Recruiting

Phase II/III

2 trials
  • Corxel Pharmaceuticals Co. Ltd. Commercial
    JX10
    2024-519521-37-01 13 countries 2025 n=287
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    GLENZOCIMAB
    2024-514352-32-00 1 country 2023 n=260
    Ended

Phase II

8 trials
  • Lumosa Therapeutics Co. Ltd. Commercial
    LT3001
    2022-502001-15-00 6 countries 2023 n=96
    Ended
  • Shionogi B.V. Commercial
    REDASEMTIDE
    2022-501890-38-00 9 countries 2024 n=238
    Recruiting
  • Clinuvel Europe Limited Academic
    AFAMELANOTIDE
    2022-500919-40-01 1 country 2023 n=12
    Ended
  • Hopital Fondation Adolphe De Rothschild Academic
    GADOBUTROL; GLENZOCIMAB
    2023-509615-92-00 1 country n=304
    Ended
  • Klinikum der Universitaet Muenchen AöR Academic
    DORNASE ALFA; SODIUM CHLORIDE
    2024-516701-22-00 1 country n=36
    Pending
  • Medical University Of Gdansk Academic
    ALTEPLASE; ANDEXANET ALFA
    2024-518509-17-00 1 country 2022 n=215
    Recruiting
  • Oslo University Hospital HF Academic
    SODIUM CHLORIDE; TOCILIZUMAB
    2025-521269-28-00 1 country n=156
    Pending
  • Unidade Local De Saude De Coimbra E.P.E. Academic
    AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE
    2025-520850-13-00 1 country n=30
    Pending

Phase IV

2 trials
  • Azienda Unita Sanitaria Locale Di Bologna Academic
    ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE HYDROCHLORIDE
    2025-523065-16-00 1 country n=1,506
    Pending
  • Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic
    ACETYLSALICYLIC ACID; CLOPIDOGREL; D,L-LYSINE ACETYLSALICYLATE; TIROFIBAN HYDROCHLORIDE MONOHYDRATE
    2023-508454-26-00 1 country 2022 n=240
    Ended

Phase I

1 trial
  • Neutrolis Inc. Commercial
    IMP not specified
    2024-512196-12-00 1 country n=72
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Assistance Publique Hopitaux De Paris Academic 2 Phase II/III, Phase III 0
Oslo University Hospital HF Academic 2 Phase II, Phase III 1
Neutrolis Inc. Commercial 1 Phase I 0
Corxel Pharmaceuticals Co. Ltd. Commercial 1 Phase II/III 1
Lumosa Therapeutics Co. Ltd. Commercial 1 Phase II 0
Shionogi B.V. Commercial 1 Phase II 1
Clinuvel Europe Limited Academic 1 Phase II 0
Hopital Fondation Adolphe De Rothschild Academic 1 Phase II 0
Klinikum der Universitaet Muenchen AöR Academic 1 Phase II 0
Medical University Of Gdansk Academic 1 Phase II 1
Unidade Local De Saude De Coimbra E.P.E. Academic 1 Phase II 0
Foundation For The Study Of Nanoneuroscience And Neuroregeneration Academic 1 Phase III 1
Karolinska Institutet Academic 1 Phase III 0
Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu Academic 1 Phase III 1
Azienda Unita Sanitaria Locale Di Bologna Academic 1 Phase IV 0
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic 1 Phase IV 0
New trials by year
2022
2
2023
3
2024
2
2025
4
← All indication landscapes